Philipp KÃ¼mpers

List of Publications by Year
in descending order

49 papers	2,931 citations	147801 31 h-index	168389 53 g-index
59 all docs	59 docs citations	59 times ranked	3735 citing authors

#	Article	IF	Citations
1	Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis, 2021, 24, 145-157.	7.2	211
2	Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study. Critical Care, 2021, 25, 112.	5.8	39
3	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis, 2021, 24, 755-788.	7.2	114
4	Protection and rebuilding of the endothelial glycocalyx in sepsis â€“ Science or fiction?. Matrix Biology Plus, 2021, 12, 100091.	3.5	10
5	Identification and validation of objective triggers for initiation of resuscitation management of acutely ill non-trauma patients: the INITIATE IRON MAN study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2021, 29, 160.	2.6	9
6	Targeting the â€œsweet spotâ€•in septic shock â€“ A perspective on the endothelial glycocalyx regulating proteins Heparanase-1 and -2. Matrix Biology Plus, 2021, 12, 100095.	3.5	18
7	Endothelial dysfunction following coronary artery bypass grafting. Herz, 2020, 45, 86-94.	1.1	8
8	Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease. Kidney International, 2020, 97, 502-515.	5.2	18
9	A Pandemic in Times of Global Tourism: Superspreading and Exportation of COVID-19 Cases from a Ski Area in Austria. Journal of Clinical Microbiology, 2020, 58, .	3.9	92
10	Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis. Critical Care, 2019, 23, 260.	5.8	79
11	Tie2 Activation Promotes Protection and Reconstitution of the Endothelial Glycocalyx in Human Sepsis. Thrombosis and Haemostasis, 2019, 119, 1827-1838.	3.4	35
12	International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs. Thrombosis Research, 2018, 166, 63-70.	1.7	18
13	Bedside analysis of the sublingual microvascular glycocalyx in the emergency room and intensive care unit â€“ the GlycoNurse study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2018, 26, 16.	2.6	67
14	The curse of angiopoietin-2 in ARDS: on stranger TI(E)des. Critical Care, 2018, 22, 44.	5.8	14
15	Endothelial glycocalyx breakdown is mediated by angiopoietin-2. Cardiovascular Research, 2017, 113, 671-680.	3.8	103
16	Vascular Endothelial Dysfunction during Cardiac Surgery: On-Pump versus Off-Pump Coronary Surgery. European Surgical Research, 2017, 58, 354-368.	1.3	19
17	Sepsis recognition in the emergency department â€“ impact on quality of care and outcome?. BMC Emergency Medicine, 2016, 17, 11.	1.9	31
18	The Synthetic Tie2 Agonist Peptide Vasculotide Protects Renal Vascular Barrier Function In Experimental Acute Kidney Injury. Scientific Reports, 2016, 6, 22111.	3.3	39

#	Article	IF	Citations
19	Intracellular RIG-I Signaling Regulates TLR4-Independent Endothelial Inflammatory Responses to Endotoxin. Journal of Immunology, 2016, 196, 4681-4691.	0.8	41
20	Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis, 2014, 234, 335-343.	0.8	174
21	Angiopoietin-2 in sepsis: lost in translation?. Nephrology Dialysis Transplantation, 2013, 28, 487-489.	0.7	3
22	Mending Leaky Blood Vessels: The Angiopoietin-Tie2 Pathway in Sepsis. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 2-6.	2.5	72
23	Nanomechanics of the Endothelial Glycocalyx in Experimental Sepsis. PLoS ONE, 2013, 8, e80905.	2.5	132
24	Angiopoietin-2 levels predict mortality in CKD patients. Nephrology Dialysis Transplantation, 2012, 27, 1867-1872.	0.7	71
25	Role of Angiopoietin/Tie2 in Critical Illness: Promising Biomarker, Disease Mediator, and Therapeutic Target?. Scientifica, 2012, 2012, 1-8.	1.7	11
26	Angiopoietin-2 in acute liver failure*. Critical Care Medicine, 2012, 40, 1499-1505.	0.9	22
27	Angiopoietin-2 is a potential mediator of endothelial barrier dysfunction following cardiopulmonary bypass. Cytokine, 2012, 60, 352-359.	3.2	29
28	The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Critical Care, 2011, 15, R261.	5.8	114
29	Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine, 2011, 55, 251-259.	3.2	84
30	Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L851-L862.	2.9	88
31	Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Medicine, 2010, 36, 462-470.	8.2	73
32	Circulating angiopoietins in idiopathic pulmonary arterial hypertension. European Heart Journal, 2010, 31, 2291-2300.	2.2	108
33	Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Critical Care, 2010, 14, R9.	5.8	111
34	Does low angiopoietin-1 predict adverse outcome in sepsis?. Critical Care, 2010, 14, 180.	5.8	13
35	The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2009, 68, 1638-1643.	0.9	66
36	Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrology Dialysis Transplantation, 2009, 24, 1845-1850.	0.7	43

#	Article	IF	Citations
37	Shock-induced stress induces loss of microvascular endothelial Tie2 in the kidney which is not associated with reduced glomerular barrier function. American Journal of Physiology - Renal Physiology, 2009, 297, F272-F281.	2.7	55
38	Angiopoietin 2 and Cardiovascular Disease in Dialysis and Kidney Transplantation. American Journal of Kidney Diseases, 2009, 53, 770-778.	1.9	64
39	Bench-to-bedside review: Angiopoietin signalling in critical illness â€“ a future target?. Critical Care, 2009, 13, 207.	5.8	101
40	Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Critical Care, 2009, 13, R64.	5.8	90
41	Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Critical Care, 2008, 12, R94.	5.8	73
42	Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Critical Care, 2008, 12, R147.	5.8	136
43	Legionnaires' disease in immunocompromised patients: a case report of Legionella longbeachae pneumonia and review of the literature. Journal of Medical Microbiology, 2008, 57, 384-387.	1.8	49
44	Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood, 2008, 112, 2139-2148.	1.4	41
45	Endothelial microparticles as a diagnostic aid in Churg-Strauss vasculitis-induced cardiomyopathy. Clinical and Experimental Rheumatology, 2008, 26, S86-9.	0.8	15
46	Leptin is a coactivator of TGF-Î² in unilateral ureteral obstructive kidney disease. American Journal of Physiology - Renal Physiology, 2007, 293, F1355-F1362.	2.7	39
47	Serum leptin and ghrelin correlate with disease activity in ANCA-associated vasculitis. Rheumatology, 2007, 47, 484-487.	1.9	26
48	Heparanase Is a Putative Mediator of Endothelial Glycocalyx Damage in COVID-19 â€“ A Proof-of-Concept Study. Frontiers in Immunology, 0, 13, .	4.8	5
49	Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study. Angiogenesis, 0, , .	7.2	8